

Lipum selected for Horizon Europe grant

Lipum announces that the company is leading a consortium that has been selected, pending final negotiations, for an EUR 8 million grant from the Horizon Europe Research and Innovation Programme, under the call “*Boosting the translation of biotech research into innovative health therapies*”. After reviewing the invitation to grant preparation, the consortium has confirmed that it meets the requirements and will proceed with the next steps in the grant agreement process.

Lipum leads the consortium together with three European partners and will use the funding to support the execution of a clinical Phase 2 proof-of-concept study of Lipum’s drug candidate SOL-116 for the treatment of moderate to severe rheumatoid arthritis.

Rheumatoid arthritis is a debilitating chronic inflammatory disease that significantly impacts patients’ quality of life and affects up to 1% of the global population, corresponding to approximately 18 million people worldwide. Lipum has identified the Bile Salt-Stimulated Lipase (BSSL) as a novel therapeutic target for rheumatoid arthritis and has developed SOL-116, a humanized monoclonal antibody directed against BSSL. SOL-116 represents a promising drug candidate with a new mechanism of action.

“We are very pleased to have been selected for this non-dilutive funding from Horizon Europe. Being chosen from a highly competitive field of innovative European companies further validates our scientific approach and underscores the potential of SOL-116 to improve outcomes for people living with rheumatoid arthritis. I would like to thank the European Commission and look forward to providing more information once the agreement has been signed,” says Ola Sandborgh, CEO of Lipum.

The *Boosting the translation of biotech research into innovative health therapies*, is designed to accelerate the translation of promising biotech research into clinical development and aims to deliver the following outcomes:

- Healthcare providers, researchers and patients get faster access to innovative therapies.
- The European Union benefits from more clinical trials being conducted with new biotech therapeutic approaches.
- The competitiveness of small and medium-sized enterprises (SMEs) from the EU and Associated Countries within the health biotech sector is strengthened.

More information on the Horizon Europe Health initiative can be found here [Cluster 1: Health - Research and innovation - European Commission](#).

PRESS RELEASE

10 March 2026 08:14:00 CET

**Contacts**

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

This information is information that Lipum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-10 08:14 CET.

Attachments

[Lipum selected for Horizon Europe grant](#)